# Envista Holdings Corporation (NVST)

**Exchange:** NYSE  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-05-29  
**Report type:** Primer (steps 1–3 of 19)  
**API endpoint:** GET /api/v1/research/NVST/primer

## Business Model

---
source: coverage-next-full
ticker: NVST
step: "01"
title: Business Overview — Envista Holdings Corporation
created: 2026-05-29
---

### Step 01 — Business Overview: Envista Holdings Corporation (NVST)

#### Company Summary
Envista Holdings Corporation is a global dental products company operating a portfolio of more than 30 brands across dental implants, orthodontics, dental equipment, and consumables. Spun off from Danaher Corporation in September 2019, Envista was designed as a standalone dental platform inheriting Danaher's operational rigor (the "Danaher Business System") while gaining strategic independence to compete across the full dental care continuum.

Headquartered in Brea, California, Envista sells products to dental practices, dental service organizations (DSOs), dental labs, and distributors in 100+ countries. Revenue in FY2025 was $2,719.5M, making it one of the largest pure-play dental products companies in the world by revenue.

#### Business Segments

##### Segment 1: Specialty Products & Technologies (~64% of FY2025 Revenue — $1,752.8M)
Higher-growth, higher-margin segment focused on implants and orthodontics.

**Dental Implants — Nobel Biocare:**
- Nobel Biocare is the flagship brand and Envista's crown jewel: a 70-year-old Swiss-founded implant manufacturer with an unmatched clinical heritage, global brand equity, and a comprehensive data library
- Products: Nobel Biocare implant systems (Nobel Parallel CC, Nobel Replace, Nobel Active), abutments, regeneration products (membranes, grafting materials), guided surgery software
- Sells to premium dental practices, university dental programs, and large DSOs
- Nobel S Series: newest generation implant system, launched to accelerate premium implant adoption
- **Implant Direct**: Value-tier implant brand — digital-only distribution targeting cost-sensitive practices; launched to capture premium-to-value migration

**Clear Aligners — Ormco / Spark:**
- Ormco is a legacy orthodontics brand (metal brackets, wires, Damon System self-ligating brackets)
- **Spark** is Ormco's clear aligner system, the growth vehicle competing with Align Technology's Invisalign
- Spark TruGEN XR: differentiated material providing superior clarity and stain resistance vs. Invisalign
- Growing from a low base — gaining market share particularly through DSOs and GP dentists
- Spark requires continued investment in orthodontist education and customer acquisition

##### Segment 2: Equipment & Consumables (~36% of FY2025 Revenue — $966.7M)
Lower-growth, more stable segment focused on dental equipment and practice supplies.

**Dental Equipment — KaVo / DEXIS:**
- KaVo: Premium dental handpieces, dental chairs, treatment units, and sterilization equipment
- DEXIS: Digital imaging brand — intraoral sensors, cone beam CT (CBCT) scanners, 3D imaging
- **DTX Studio**: Envista's open digital workflow platform connecting imaging, implant planning, and guided surgery; positioned as the ecosystem hub across brands

**Dental Consumables — Kerr / Other:**
- Kerr: Restoratives (composites, bonding agents), endodontic files, infection control products
- Other brands: Meisinger (rotary instruments), Pelton & Crane (operatory equipment), Sola (laboratory products)

#### Corporate Heritage and DNA
- **Danaher Connection:** Envista was built from Danaher's dental business (acquired Sybron Dental 2011, Nobel Biocare 2014, Ormco pre-2019). Inherited the Danaher Business System (DBS): a continuous improvement, kaizen-based operational framework that drives lean manufacturing, quality management, and growth through acquisition integration
- **Post-Spinoff Ownership:** Danaher initially retained ~17% ownership post-spinoff; has since sold down to immaterial level
- **IPO Structure:** Envista raised ~$784M in its September 2019 IPO on NYSE

#### Geographic Footprint
- **United States:** Largest single market; DSO channel is fastest-growing go-to-market
- **Europe:** Germany, Switzerland, Netherlands, France, UK — strong implant and equipment presence; Nobel Biocare heritage particularly strong
- **Asia-Pacific including China:** ~20–25% of total revenue; China is largest APAC market and source of significant VBP-related headwind since 2023
- **Rest of World:** Latin America, Middle East, other emerging markets (smaller but growing)

#### Go-to-Market Model
- **Direct sales force:** Calls on dental specialists (periodontists, oral surgeons, prosthodontists) and orthodontists for premium products
- **DSO sales:** Dedicated DSO team targeting group practices and large dental chains; increasingly important channel as DSO consolidation accelerates
- **Distribution:** Third-party dental distributors (Henry Schein, Patterson, Benco) for consumables and equipment
- **Digital/direct:** Implant Direct operates as a digital-first, direct-to-dentist model for value implants

#### Key Brands Summary
| Brand | Category | Position |
|-------|----------|----------|
| Nobel Biocare | Premium implants | Global #1 premium implant brand |
| Implant Direct | Value implants | Low-cost digital-direct implant |
| Ormco | Traditional orthodontics | Damon self-ligating system |
| Spark | Clear aligners | Growing Invisalign competitor |
| KaVo | Dental equipment | Premium handpieces/chairs |
| DEXIS | Digital imaging | Intraoral + CBCT imaging |
| DTX Studio | Digital workflow software | Open platform connecting portfolio |
| Kerr | Consumables | Composites, bonding, endo |

#### Strategic Narrative (2024–2026)
Management under CEO Amir Aghdaei is executing a "portfolio-led recovery" strategy: (1) prioritize the Specialty Products segment (higher margins, faster growth) over Equipment & Consumables; (2) expand operating leverage from the depressed post-VBP/post-Spark-investment trough; (3) return capital via a now-active buyback program ($300M authorized May 2026); and (4) use DTX Studio as the digital ecosystem to deepen multi-brand relationships with DSOs and specialists.

The company targets adj. EBITDA margins of 17–20% over a multi-year horizon (vs. 13.7% in FY2025), implying ~400–600bps of margin expansion from operational leverage and mix shift as Specialty Products grows faster than Equipment & Consumables.

## Financial Snapshot

---
source: coverage-next-full
ticker: NVST
step: "04"
title: Financial Snapshot — 5-Year P&L Summary
created: 2026-05-29
---

### Step 04 — Financial Snapshot: 5-Year P&L Summary

#### Annual Income Statement Summary (USD millions)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|--------|--------|--------|--------|--------|--------|
| Revenue | $2,509 | $2,569 | $2,567 | $2,511 | $2,720 |
| Gross Profit | $1,427 | $1,475 | $1,441 | $1,373 | $1,487 |
| Gross Margin | 56.9% | 57.4% | 56.1% | 54.7% | 54.7% |
| R&D Expense | $101 | $100 | $94 | $99 | $114 |
| Operating Income (GAAP) | $306 | $319 | $32 | -$1,038 | $216 |
| Operating Margin (GAAP) | 12.2% | 12.4% | 1.2% | -41.3% | 7.9% |
| Net Income (GAAP) | $341 | $243 | -$100 | -$1,119 | $47 |
| EPS (Diluted, GAAP) | $1.92 | $1.37 | -$0.60 | -$6.50 | $0.28 |
| Adj. EBITDA | $430 | $457 | ~$170 | ~$295* | $372 |
| Adj. EBITDA Margin | 17.1% | 17.8% | ~6.6% | ~11.7%* | 13.7% |
| Adj. EPS | ~$2.10 | ~$2.20 | ~$0.73 | ~$0.73 | $1.19 |

*FY2024 GAAP figures distorted by ~$1.15B goodwill impairment charge; adj. EBITDA excludes impairment

#### Key Observations on the P&L

##### Gross Margin Compression
Gross margins peaked at 57.4% in FY2022 and have compressed to 54.7% in FY2024–FY2025. The compression reflects:
1. **China VBP:** Nobel Biocare products subject to procurement pricing absorbed pricing cuts while fixed manufacturing costs remained; absorbed as gross margin contraction
2. **Mix shift:** Faster growth in lower-margin Spark (still in investment phase) and value-tier Implant Direct
3. **Inflationary costs:** Material and labor cost inflation in 2022–2023 passed through slower than expected in China
4. Management targets gross margin recovery toward 56–58% range through product mix improvement and manufacturing efficiencies

##### Operating Leverage Collapse (FY2023–FY2024) Then Partial Recovery (FY2025)
- FY2023: GAAP operating income collapsed to $32M (1.2% margin) from $319M in FY2022
  - Drivers: China VBP pricing impact ($75–100M revenue headwind), Spark investment ramp ($50–75M incremental OpEx), FX headwinds, dental market softness
- FY2024: GAAP operating income was -$1,038M, but this is almost entirely explained by a $1.15B non-cash goodwill impairment charge
  - Adjusted EBITDA (excl. impairment): ~$295M (11.7% margin) — still compressed but not negative
- FY2025: Meaningful recovery. GAAP operating income $216M (7.9% margin); Adj. EBITDA $372M (13.7% margin; +26% YoY)
  - Revenue recovery of +8.3% drove operating leverage; Spark investment less dilutive as scale grows

##### Non-Cash Goodwill Impairment — FY2024
- Envista took a ~$1.15B goodwill impairment in FY2024, primarily related to the Equipment & Consumables segment
- Triggered by: persistent stock price below book value, elevated interest rates raising discount rates, subdued dental equipment demand
- This was a non-cash charge that eroded book equity but did not impact cash generation
- Following the impairment, goodwill declined from $3,292M (FY2023) to $2,262M (FY2024)
- The impairment reflects real headwinds in the E&C segment but overstates the cash flow deterioration

##### Adjusted vs. GAAP — Why Adjusted Matters Here
Envista's GAAP figures are heavily distorted by: (1) goodwill impairments, (2) amortization of acquisition intangibles (~$150–175M/year), (3) restructuring charges, and (4) acquisition-related costs. Adjusted EBITDA and adjusted EPS are more relevant for ongoing cash-generative power analysis:

| Metric | FY2023 | FY2024 | FY2025 |
|--------|--------|--------|--------|
| GAAP Operating Income | $32M | -$1,038M | $216M |
| Adjusted EBITDA | ~$170M | ~$295M | $372M |
| Adj. EBITDA Margin | ~6.6% | ~11.7% | 13.7% |
| Adj. EPS | ~$0.73 | ~$0.73 | $1.19 |

Note: The FY2023 adj. EBITDA of ~$170M reflects the real operational deterioration from VBP + Spark investment; FY2024 adjusted was ~$295M (partially recovered). FY2025 accelerated to $372M.

#### Earnings Per Share Trend
| Fiscal Year | GAAP EPS (Diluted) | Adj. EPS | Shares Out. (Avg.) |
|-------------|-------------------|----------|-------------------|
| FY2021 | $1.92 | ~$2.10 | 177.5M |
| FY2022 | $1.37 | ~$2.20 | 177.2M |
| FY2023 | -$0.60 | ~$0.73 | 172.3M |
| FY2024 | -$6.50 | ~$0.73 | 172.2M |
| FY2025 | $0.28 | $1.19 | 167.5M |
| FY2026E | ~$0.95E | ~$1.40E | ~161M (est.) |

Adjusted EPS is the appropriate operating metric. The trajectory from $0.73 (FY2023/FY2024 trough) to $1.19 (FY2025) to $1.40E (FY2026E) represents a 91% improvement from trough to consensus estimate — a strong earnings recovery thesis.

#### R&D Investment
R&D spending is relatively stable at $94–114M annually (~3.7–4.2% of revenue). Key areas:
- Nobel S Series next-generation implant system
- Spark TruGEN XR aligner material and treatment planning software
- DEXIS AI imaging algorithms
- DTX Studio platform development

#### Profitability Path to Target
Management's long-term adj. EBITDA margin target of 17–20% (vs. 13.7% in FY2025) implies:
- ~$310–360M of additional annual EBITDA at current revenue scale
- Requires both revenue growth (mix shift to Specialty) AND cost efficiency (SG&A leverage as Spark investment matures)
- Comparable to Straumann's ~25%+ EBITDA margins (best-in-class) and Align's ~28–30% — Envista's target is achievable if Spark reaches scale

## Recent Catalysts

---
source: coverage-next-full
ticker: NVST
step: "12"
title: Catalysts & Investment Thesis Summary
created: 2026-05-29
---

### Step 12 — Catalysts & Investment Thesis Summary

#### Near-Term Catalysts (Next 12 Months)

##### 1. Continued Earnings Recovery — Guidance Beat Potential
Company FY2026 guidance: adj. EPS $1.35–$1.45, core sales growth 2–4%. Given Q1 2026 core growth of 9.5% and adj. EPS of $0.36 (annualized $1.44), guidance appears conservatively set. If the recovery trend continues, Q2–Q4 2026 results could produce consensus-beating results. Consistent beats drive multiple expansion — NVST is trading at 17x forward P/E (vs. dental peer average ~25–30x).

##### 2. China Volume Recovery — Positive VBP Read-Through
China's lower post-VBP implant prices are expected to drive volume expansion as implant procedures become more affordable to the middle-class population. Volume data from market checks in 2025 suggests China implant procedure volumes are growing mid-single-digits from the price-reduced base. As this volume normalizes and Envista's China business stabilizes, the VBP overhang — which has been a structural discount to the stock — should lift.

##### 3. $300M Share Repurchase Execution
The May 2026 $300M authorization combined with prior program creates a catalyst: if Envista deploys $250–300M in repurchases over 12–18 months at current prices (~$23–24/share), it retires ~12–13M shares (~7–8% of float). Combined with earnings growth, this creates double-digit EPS per-share growth even in a modest revenue environment. Buyback activity is a concrete signal of management's intrinsic value conviction.

##### 4. Nobel S Series Adoption Traction
The Nobel S Series is the newest generation implant platform, offering improved primary stability, simplified surgical technique, and aesthetic outcomes. Early clinical data and customer feedback from KOL dentists is positive. Increasing adoption in 2026 would: (a) support Specialty Products revenue growth, (b) drive trading-up within Nobel's own customer base (higher ASP), and (c) generate favorable clinical publication pipeline for peer-reviewed moat reinforcement.

##### 5. Spark Aligner Market Share Data
Any quantitative disclosure from Envista (or triangulated from Align's quarterly disclosures) showing Spark gaining meaningful share — particularly in the DSO channel — would be a positive catalyst. Align has referenced competitive pricing pressure in certain channels, which indirectly validates Spark's progress.

##### 6. Versah Integration + Future Tuck-In Acquisitions
The Versah acquisition (Q1 2026) is small but demonstrates Envista's ability to identify and integrate bolt-on assets. Additional tuck-ins that enhance the Specialty Products portfolio without requiring large goodwill premiums would be strategically and financially positive.

---

#### Medium-Term Catalysts (1–3 Years)

##### 7. Margin Expansion Toward 17–20% EBITDA Target
Management's stated multi-year adj. EBITDA margin target of 17–20% (vs. 13.7% in FY2025) represents a ~320–630bps expansion. Achieving the low end of this range would add ~$85M to annual EBITDA at current revenue. The market is not pricing in this margin expansion — multiple expansion would follow as credibility builds.

##### 8. Spark Reaching Scale / DSO Penetration
If Spark achieves critical mass in the DSO channel (>10% aligner market share with major DSO groups), the unit economics improve dramatically — training costs are sunk, per-case profitability increases, and the brand begins to develop patient pull rather than just practice push.

##### 9. China Market Re-Expansion
Over 3–5 years, the dramatically lower post-VBP implant prices should result in volume normalization and potential growth. China's dental implant penetration is still ~10–20% of Western markets — the absolute ceiling for volume growth is large.

##### 10. Portfolio Simplification / E&C Divestiture Option
Equipment & Consumables is lower-growth, lower-margin, and lacks a strong moat. If activist pressure (Lin Tan's ~18.8% block) pushes for portfolio streamlining, a divestiture of non-core E&C brands (Kerr consumables, Meisinger, Pelton & Crane) could crystalize value and allow Envista to become a pure-play implant/aligner company at a premium multiple.

---

**Bull Case**
- China volume recovery accelerates faster than expected as post-VBP penetration expands; VBP proves to be a medium-term catalyst rather than a structural headwind; China revenue grows 15–20% annually 2026–2028 driving total company core growth to 7–9%
- Spark aligner achieves 10%+ clear aligner market share in DSO channel by 2028 through superior economics and product differentiation, Spark EBITDA contribution turns positive eliminating the earnings drag and driving 200–300bps incremental margin expansion
- Nobel S Series + DTX Studio create a digital ecosystem moat at scale DSOs, generating 3–5 year multi-brand contracts that lock in $500M+ of recurring high-margin revenue; combined with buybacks, adj. EPS reaches $2.50–3.00 by 2028 against a stock trading at 20–22x = $50–66/share (+110–180% upside)

**Bear Case**
- China VBP expands to clear aligners and dental equipment in 2026–2027, delivering a second wave of revenue and margin compression across Specialty Products and Equipment & Consumables, resetting the recovery narrative and adding $100–150M in headwinds that overwhelm organic growth
- Spark fails to meaningfully penetrate the DSO market beyond early adopters as Align Technology responds with competitive pricing and expanded GP dentist programs, forcing Envista to either cede the market or sustain indefinite heavy investment; adj. EBITDA margins stall at 14–15% well below the 17–20% target
- A US recession in 2026–2027 causes elective dental procedure volumes to contract 15–20%, hitting implant and aligner revenue hardest; combined with FX headwinds and tariff costs, FY2027 revenue falls below FY2025 levels and the margin recovery reverses, causing the stock to re-rate to 10–12x forward EBITDA = $15–18/share (-25–35% downside)

## Full Research Available

This primer covers steps 1–3 of 19. The full deep dive (moat analysis, DCF, bull/bear,
management quality, earnings transcript analysis) is available via:

- Investment memo: /memo/nvst
- Full research API: GET /api/v1/research/NVST/memo
- Coverage universe: /stocks